Last reviewed · How we verify

Azd5363 — Competitive Intelligence Brief

Azd5363 (azd5363) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: phosphatidylinositol 3-kinase (PI3K) inhibitor. Area: Oncology.

marketed phosphatidylinositol 3-kinase (PI3K) inhibitor AKT Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Azd5363 (azd5363) — Pfizer.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Azd5363 TARGET azd5363 Pfizer marketed phosphatidylinositol 3-kinase (PI3K) inhibitor AKT
Placebo followed by Fisetin Placebo followed by Fisetin Wake Forest University Health Sciences marketed Senolytic agent Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
QL1706 QL1706 Fujian Cancer Hospital phase 3 PI3K/AKT pathway inhibitor PI3K/AKT pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (phosphatidylinositol 3-kinase (PI3K) inhibitor class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azd5363 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd5363. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: